13 results for "Sebastian P. Fuchs"

Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies

Sebastian P Fuchs; Ronald C Desrosiers

Molecular Therapy: Methods & Clinical Development, Vol. 3 No. C · 2016 · English · DOAJ

Attempts to elicit antibodies with potent neutralizing activity against a broad range of human immunodeficiency virus (HIV) isolates have so far proven unsuccessful. Long-term delivery of monoclonal antibodies (mAbs) with such activity is a creative alternative that circumvents the need for an…

Recombinant AAV Vectors for Enhanced Expression of Authentic IgG.

Sebastian P Fuchs; José M Martinez-Navio; Guangping Gao et al.

PLoS ONE, Vol. 11 No. 6 · 2016 · English · DOAJ Scopus

Adeno-associated virus (AAV) has become a vector of choice for the treatment of a variety of genetic diseases that require safe and long-term delivery of a missing protein. Muscle-directed gene transfer for delivery of protective antibodies against AIDS viruses and other pathogens has been used…

Also available at: PLOS

Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity

James M. Termini; José M. Martinez-Navio; Guangping Gao et al.

Molecular Therapy: Methods & Clinical Development, Vol. 20 · 2021 · English · DOAJ

The absence of fucose on asparagine-297 of the human immunoglobulin G (IgG) heavy chain has been shown to enhance antibody-dependent cellular cytotoxicity (ADCC) activity by 10- to 100-fold compared to fucosylated antibody. Our lab is studying the use of adeno-associated virus (AAV) as a vector for…

Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys

Sebastian P. Fuchs; José M. Martinez-Navio; Eva G. Rakasz et al.

Molecular Therapy: Methods & Clinical Development, Vol. 16 · 2020 · English · DOAJ

A number of publications have described the use of adeno-associated virus (AAV) for the delivery of anti-HIV and anti-simian immunodeficiency virus (SIV) monoclonal antibodies (mAbs) to rhesus monkeys. Anti-drug antibodies (ADAs) have been frequently observed, and long-term AAV-mediated delivery…

AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity.

Sebastian P Fuchs; José M Martinez-Navio; Michael Piatak et al.

PLoS Pathogens, Vol. 11 No. 8 · 2015 · English · DOAJ Scopus

Long-term delivery of potent broadly-neutralizing antibodies is a promising approach for the prevention of HIV-1 infection. We used AAV vector intramuscularly to deliver anti-SIV monoclonal antibodies (mAbs) in IgG1 form to rhesus monkeys. Persisting levels of delivered mAb as high as 270 μg/ml…

Also available at: PLOS

High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes

Matthew R. Gardner; Desiree E. Mendes; Claudia P. Muniz et al.

Molecular Therapy: Methods & Clinical Development, Vol. 24 · 2022 · English · DOAJ

Prescreening of participants in clinical trials that use adeno-associated virus (AAV) vectors is required to identify naive participants, as preexisting neutralizing antibodies can limit the efficacy of AAV gene therapies. The presence of antibodies to individual AAV serotypes is typically detected…

Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV

José M. Martinez-Navio; Sebastian P. Fuchs; Desiree E. Mendes et al.

Frontiers in Immunology, Vol. 11 · 2020 · English · DOAJ Scopus

Long-term delivery of anti-HIV monoclonal antibodies using adeno-associated virus (AAV) holds promise for the prevention and treatment of HIV infection. We previously reported that after receiving a single administration of AAV vector coding for anti-SIV antibody 5L7, monkey 84-05 achieved high…

Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies

Sebastian P. Fuchs; Paula G. Mondragon; Rachel Zabizhin et al.

Nature Communications, Vol. 16 No. 1 · 2025 · English · DOAJ Scopus

Abstract Long-term delivery of broadly neutralizing antibodies (bnAbs) using adeno-associated virus (AAV) vector is a promising approach for both the prevention and treatment of HIV infection. However, host anti-drug antibody (ADA) responses severely limit the continuous delivery of these anti-HIV…

Induction of Transient Virus Replication Facilitates Antigen-Independent Isolation of SIV-Specific Monoclonal Antibodies

Nuria Pedreño-Lopez; Christine M. Dang; Brandon C. Rosen et al.

Molecular Therapy: Methods & Clinical Development, Vol. 16 · 2020 · English · DOAJ

Structural characterization of the HIV-1 Envelope (Env) glycoprotein has facilitated the development of Env probes to isolate HIV-specific monoclonal antibodies (mAbs). However, preclinical studies have largely evaluated these virus-specific mAbs against chimeric viruses, which do not naturally…

A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus

Diogo M. Magnani; Cassia G. T. Silveira; Brandon C. Rosen et al.

PLOS Neglected Tropical Diseases, Vol. 11 No. 6 · 2017 · English · PLOS Scopus

The isolation of neutralizing monoclonal antibodies (nmAbs) against the Zika virus (ZIKV) might lead to novel preventative strategies for infections in at-risk individuals, primarily pregnant women. Here we describe the characterization of human mAbs from the plasmablasts of an acutely infected…

Also available at: DOAJ